Significance of lipoprotein(a) in diabetic chronic renal failure

Vasanthan M.

doi:10.18203/2320-6012.ijrms20173695

Authors

Vasanthan M. Department of Biochemistry, SRM Medical College Hospital and Research Centre, SRM University, Kattankulathur, Tamilnadu, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20173695

Keywords:

Chronic renal failure, Lipoprotein(a)

Abstract

Background: Diabetes mellitus, is a metabolic disease with an alarming prevalence worldwide. When uncontrolled, this can result in diseases such as chronic renal failure by various atherogenic factors including lipoprotein(a). Aim was to estimate the level of lipoprotein(a) in diabetic chronic renal failure patients and to correlate with healthy controls.

Methods: 30 non-diabetic subjects and 30 diabetic CRF patients were included in the study. Lipoprotein(a) was estimated by immunoturbidimetric method and the other parameters by their respective methods in biochemistry auto-analyzer.

Results: It was found from the study that there is a positive correlation of lipoprotein(a) levels with the duration of diabetes and was progressive with the diabetic complications.

Conclusions: Lipoprotein(a) is responsible for atherogenic events in CRF patients.

Metrics

Metrics Loading ...

References

Mbewu AD, Durington PN. Lipoprotein(a): Structure and possible involvement in thrombogenesis and atherosclerosis. Atherosclerosis. 1999;85:1-14.

Kamstrip PR, Nordestgard BG. Extreme lipoprotein(a) levels and myocardial infarction. Circulation. 2008;117:176-84.

Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. "Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it". EMBO J. 1989;8(13):4035-40.

Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. "Lipoprotein(a) as a cardiovascular risk factor: current status". Eur. Heart J. 2010;31(23):2844-53.

Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. "Lipoprotein(a) and risk of myocardial infarction--genetic epidemiologic evidence of causality". Scand J Clin Lab Invest. 2011;71(2):87-93.

Danesh J, Collins R, Peto R. "Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies". Circulation. 2000;102(10):1082-5.

Smolders B, Lemmens R, Thijs V. "Lipoprotein (a) and stroke: a meta-analysis of observational studies". Stroke. 2007;38(6):1959-66.

Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, et al. "Lipoprotein(a) as a risk factor for preclinical atherosclerosis". Arterioscler. Thromb. 1993;13(6):826-33.

Berg K. "A new serum type system in man- the Lp system". Acta Pathol Microbiol Scand. 1963;59(3): 369-82.